Alkermes Plc (Alkermes) is a biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for treating opioid dependence, schizophrenia, bipolar I disorder, alcohol dependence, and narcolepsy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

-Alkermes is committed to advancing scientific research with the potential to significantly impact patients, focusing on developing product candidates for psychiatric and neurological disorders. The company's R&D pipeline includes investigational product candidates and investigational uses of approved products that have not yet been approved by health authorities. The pipeline features products such as sodium oxybate extended-release oral suspension for idiopathic hypersomnia, olanzapine and samidorphan for schizophrenia and bipolar I disorder (pediatric), alixorexton for narcolepsy types 1 and 2 and idiopathic hypersomnia, ALKS 4510 for fatigue in neurodegenerative disorders, ALKS 7290 for attention-deficit hyperactivity disorder, and valiloxybate for narcolepsy and idiopathic hypersomnia. The R&D unit of Alkermes is located in Waltham, Massachusetts, where the company leases a 231,000 square foot corporate office and R&D center. This unit is responsible for managing the company's research and development activities. Alkermes has one R&D center located in Waltham, Massachusetts. The company holds several U.S. patents and patent applications, with numerous corresponding non-U.S. counterparts. The pipeline includes multiple products under development, and the company has established major technology alliances through exclusive licensing agreements with third parties. In FY2025, the company spent US$323.9 million on its R&D activities, which as a percentage of revenue stood at 22%, grew by 32.1% YoY.